Background/Objectives: Dietary addition of either conjugated linoleic acid (CLA) or n-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFAs) has been shown to alter adiposity and circulating lipids, risk markers of cardiovascular diseases. However, CLA may decrease insulin sensitivity, an effect that may be reversed by n-3 LC-PUFA. Thus, the potential of CLA plus n-3 LC-PUFA to affect insulin secretion and sensitivity in non-diabetic young and old, lean and obese subjects was tested. Subjects/Methods: CLA (3 g daily) plus n-3 LC-PUFA (3 g daily) or control oil (6 g daily) was given to lean (n ¼ 12; BMI 20-26 kg/m 2 ) or obese (n ¼ 10; BMI 29-35 kg/m 2 ) young (20-37 years old) or lean (n ¼ 16) or obese (n ¼ 11) older men (50-65 years) for 12 weeks. The study had a double-blind, placebo-controlled randomized crossover design, and primary end points were insulin secretion and sensitivity during a standardized meal test, evaluated by modeling glucose, insulin and C-peptide data. Results: The combination was well tolerated. There was no significant difference in fasting levels of glucose, insulin or C-peptide after CLA/n-3 LC-PUFA treatment compared with control oil. Neither insulin secretion nor estimated sensitivity was affected by CLA/n-3 LC-PUFA in lean or obese young subjects or in older lean subjects. However, in older obese subjects, estimated insulin sensitivity was reduced with CLA/n-3 LC-PUFA compared with control (P ¼ 0.024).
Introduction
There is considerable interest in conjugated linoleic acid (CLA) and n-3 polyunsaturated fatty acids (n-3 LC-PUFAs) due to their reported beneficial effects on energy metabolism and insulin sensitivity associated with weight loss (Wang and Jones, 2004; Salas-Salvado et al., 2006; Sörhede Winzell and Ahrén, 2007) . Evidence in rodents shows that CLA reduces fat mass, hyperglycemia and hyperlipidemia and increases insulin sensitivity (Park et al., 1997; Houseknecht et al., 1998; West et al., 1998; Hamura et al., 2001; Ryder et al., 2001; Roche et al., 2002) . Long-term studies in rodents, however, demonstrate a marked lipodystrophic effect of CLA with reduced adiponectin expression associated with insulin resistance (DeLany and West, 2000; Tsuboyama-Kasaoka et al., 2000; Roche et al., 2002) . Fish oil, which is rich in n-3 LC-PUFAs, reduces obesity and has beneficial effects on energy metabolism in rodent studies (Ruxton, 2004; Ruzickova et al., 2004; Poirier et al., 2005) and reverses the effects of CLA on energy metabolism in mice (Ide, 2005) . However, it has recently been shown that supplementation with a 50:50 combination of CLA and n-3 LC-PUFA was lipoatrophic and greatly increased insulin insensitivity in mice, but not on a high-fat diet (Sörhede Winzell et al., 2006) , indicating that diet and adiposity may influence the effect of the supplementation.
In humans, CLA has been shown both to reduce (Blankson et al., 2000) and to have no effect on body weight (Larsen et al., 2003) in overweight or diabetic subjects and to reduce insulin sensitivity but improve dyslipidemia in type 2 diabetes (Moloney et al., 2004) . CLA has also been reported to reduce insulin sensitivity in already insulin-insensitive subjects (Risérus et al., 2002; Moloney et al., 2004) . Studies have shown beneficial effects of fish oil on energy metabolism in humans (Delarue et al., 2006; Lombardo and Chicco, 2006) , whereas other studies show no beneficial effect (Farmer et al., 2000; Balk et al., 2006) .
Both n-3 LC-PUFAs and CLAs are readily available as dietary supplements and individuals may take both in the belief that a combination will result in an additive effect on body weight, insulin sensitivity and dyslipidemia. However, no reports exist on the effects of the combination of CLA and n-3 LC-PUFA in humans. Considering the results of studies using CLA and n-3 LC-PUFA individually in humans and in combination in rodents and the influence that differing adiposity and dietary fat may have, we tested the hypothesis that supplementation with a combination of CLA and n-3 LC-PUFA in humans may have beneficial additive effects while avoiding the unfavorable effect on insulin sensitivity reported for CLA alone. The additional effect of age and adiposity on these outcomes was also tested.
In this study therefore, healthy young and older, lean and obese subjects were recruited to determine the effect of a 12-week supplementation with a combination of CLA/n-3 LC-PUFA on insulin secretion and sensitivity and whether there were any effects of age or adiposity. Insulin secretion and insulin sensitivity are central to both glucose homeostasis and the pathophysiological processes in the development of glucose intolerance and type 2 diabetes (Kahn, 2003; Ahrén and Pacini, 2004) . Previously validated models were used to estimate insulin secretion and action after ingestion of a mixed meal (Mari et al., 2002a (Mari et al., , b, 2005a . Caucasian men (aged 50-65 years) were recruited. All subjects were non-diabetic, non-smokers and were not taking any drugs. Furthermore, all subjects were in good health, as determined by medical history, physical examination and screening blood tests. Exclusion criteria included hypertension, coronary heart disease, pancreatic disease and any acute illness. Particular care was taken to exclude recent use of aspirin and dietary antioxidant supplements and recent changes in body weight (44 kg) within the last 3 months. The study was approved by the Grampian Research Ethics Committee (UK) and written informed consent was obtained from all participants.
Materials and methods

Subjects
Design of the study The study was a randomized double-blind crossover design. The subjects were randomized to receive either control oil or CLA/n-3 LC-PUFA supplementation and a meal test before supplementation was carried out. After 12 weeks, on the last day of supplementation, a second meal test was undertaken followed by a 12-week washout period before a third meal test and a second period of supplementation started, that is, control oil in subjects who had CLA/n-3 LC-PUFA during the first 3 months and CLA/n-3 LC-PUFA in those who had control oil during the first 3 months. Following the second supplementation period, a fourth meal test was performed. All participants were asked to maintain their usual dietary and lifestyle habits, and the effect of changes in diet, weight and physical activity was explained to the subjects. Estimates of physical activity and food intake were based on personal diaries and from analysis of recordings taken from a miniature uniaxial accelerometer (Actiwatch; Cambridge Neurotechnology Ltd, Cambridge, UK) worn on the nondominant wrist of each subject and on dietary intakes based on food-weighed records, each completed within 7 days before the start and 7 days before the end of each 12-week supplementation period.
Meal tests
After 12 h overnight fast, subjects were admitted to the Human Nutrition Unit (RRI). An intravenous catheter placed in an antecubital vein was kept patent by a slow (0.5 ml/min) infusion of isotonic saline. After a short resting period, a standard breakfast meal consisting of three slices of bread (95 g), low-fat cheddar cheese (27 g), one slice of smoked ham (10 g), marmalade or jam (15 g), sunflower spread (18 g) and instant coffee (2 g) or tea (water 200 g) with milk (30 g) was served. The meal contained 448 kcal; energy was derived from protein (18.2%), carbohydrate (55.9%) and fat (25.9%) and was consumed under supervision. Blood samples were taken immediately before the start of meal ingestion and after 30, 60, 90, 120 and 180 min.
Dietary supplementation
Volunteers received either 3 g n-3 LC-PUFA plus 3 g CLA per day or 6 g control oil mixture. The n-3 LC-PUFA mixture was in the form of EPAX 5500TG kindly supplied by Pronova Biocare (Lysaker, Norway) and contained 300 mg/g eicosapentanoic acid C20:5 and 210 mg/g docosahexaenoic acid C22:6 (docosahexaenoic acid). The CLA was Clarinol G-80 and consisted of 760 mg CLA/g with a 50:50 mixture of the cis-9,trans-11 (c-9, t11) isomer (350 mg/g) and the trans-10,cis-12 (t-10,c-12) isomer (350 mg/g) and was kindly supplied by Loders Croklaan (now Lipid Nutrition; Wormerveer, The Netherlands). The control oil consisted of 200 mg/g soy bean oil and 800 mg/g palm oil (Cardinal Health, Swindon, UK). The fatty acid composition of the control fat was specifically chosen to represent the fatty acid profile present in the average UK diet (41% saturated fatty acid: 36% monounsaturated fatty acid: 21% PUFA in the control fat vs 38% saturated fatty acid: 33% monounsaturated fatty acid: 21% PUFA in the average diet). The 6 g of total fat present in each of the supplements given each day represents an increase of approximately 2.5% of the average total daily energy intake of a male in the United Kingdom (Henderson et al., 2003) . All supplements were in 1 g capsules, that is, six capsules were ingested each day with two capsules taken with each of the three daily meals. Volunteers were assigned to either CLA/n-3 LC-PUFA or control oil supplementation in a double-blind manner. Nonconsumed capsules were counted to monitor compliance and analysis of n-3 LCPUFA content in blood cell membranes from a random selection volunteers before and after supplementation was also carried out. Compliance did not differ between the treatment groups: 99 and 98% of supplements were used by the control oil and CLA/n-3 LC-PUFA groups, respectively. The CLA/n-3 LC-PUFA combination was well tolerated. Twelve subjects dropped out of the study: six due to the study intensity/duration, two due to difficulty in swallowing the capsules and four were excluded for medical reasons during the study (for example, blood pressure medication).
Measurements and assays
Waist and hip circumferences were assessed and body weight and height were measured using a scale and a stadiometer to the nearest 0.5 kg and 0.5 cm, respectively. Brachial blood pressure (average of three measurements) was recorded using an automatic digital blood pressure monitor while seated (Omron Healthcare UK Ltd, Keynes, UK). Venous blood was collected in EDTA vacutainers. Plasma was separated and stored at À20 1C until analysis. Plasma non-esterified fatty acids, cholesterol and triglycerides were determined spectrophotometrically (Wako Chemicals Inc., Richmond, VA, USA; Konelab Corporation, Espoo, Finland; and Thermo Clinical Labsystems, Espoo, Finland). Plasma insulin and C-peptide concentrations were analyzed with double-antibody radioimmunoassay techniques (Linco Res., St Charles, MO, USA) and glucose was determined by the glucose oxidase technique (Bruss and Black, 1978) .
Calculation and statistics b-Cell function parameters were obtained by modeling data (Mari et al., 2002a, b) . Insulin secretion was determined by C-peptide deconvolution (Van Cauter et al., 1992) . The model expresses insulin secretion as the sum of two components. The first describing the relationship between insulin secretion and absolute glucose concentration at any time point, that is, a dose-response function. The mean slope of the dose-response function represents b-cell glucose sensitivity. Insulin secretion at reference glucose levels representing the average basal glucose concentration of 5 mmol/l, approximately the average basal glucose, was calculated from the b-cell dose response. This is modulated by a time-varying factor. The potentiation factor that encompasses various potentiating signals (glucose-induced potentiation, incretins and neural factors) was set to have a mean value equal to unity over the 3 h of the study. As the potentiation factor typically increases during a meal, the ratio between the potentiation factor value at 3 h and that at time 0 was used as a parameter quantifying potentiation. The second insulin secretion component represents a dynamic dependence of insulin secretion on the rate of change of glucose concentration. It is proportional to the time derivative of glucose concentration when glucose rises and is zero otherwise. The proportionality constant, termed rate sensitivity, accounts for anticipation of insulin secretion as glucose levels rise. The potentiation factor and total insulin secretion (expressed in pmol/min per square meter of body surface area) were calculated every 5 min for the whole 3 h period.
Insulin sensitivity was determined from meal glucose and insulin concentrations using oral glucose insulin sensitivity, which represents a validated measure of glucose clearance (ml/ min/m 2 ) obtained during euglycemic, hyperinsulinemic glucose clamp (Mari et al., 2001 (Mari et al., , 2005b . Oral glucose insulin sensitivity has previously been shown to yield results of insulin sensitivity, which are similar to the euglycemic clamp test, and to fully be consistent with established physiological principles (Mari et al., 2001) . Furthermore, when comparing five different methods for calculation of insulin sensitivity vs the euglycemic hyperinsulinemic clamp, it was found that oral glucose insulin sensitivity was preferable over other methods (Mari et al., 2005b) . Baseline measurements between groups were compared using one-way analysis of variance and unpaired t-tests. Statistical analysis was carried out to determine whether there were any effects of treatment sequence as a result of the crossover design. No treatment-by-period interactions were observed (data not shown). Thus, all data were treated as paired samples from a crossover study, and the differences between control fat and CLA/n-3 LC-PUFA treatments were examined by using paired t-tests on the change between 0-and 12-week measurements. The effects of treatment (differences between the changes from baseline) were evaluated by analysis of variance with Bonferroni post hoc analysis within the four study groups, that is, effects of CLA/ n-3 LC-PUFA vs control oil were compared within each group. Table 1 shows the characteristics of the subjects and baseline data. Obese subjects had higher levels of insulin and C-peptide, regardless of age. During baseline meal tests, obese subjects had higher AUC insulin , AUC C-peptide , fasting and total insulin secretory rate, but lower insulin sensitivity (Table 2) . Glucose, insulin and C-peptide concentrations after meal ingestion were not significantly different before treatment with CLA/n-3 LC-PUFA or control oil in young and older subjects (not shown). Physical activity, mean daily energy, macronutrient, dietary fiber, cholesterol, PUFA, alcohol intake and percentage contributions to total energy did not differ significantly across either CLA/n-3 LC-PUFA or control treatment within groups (not shown).
Results
Subject characteristics
Effects of CLA/n-3 LC-PUFA or control oil in young subjects After treatment in the young subjects, glucose, insulin and C-peptide concentration curves after meal ingestion were almost superimposable, with no significant difference between groups at any time point. None of the metabolic parameters changed significantly after CLA/n-3 LC-PUFA or control oil supplementation (Table 3) , indicating CLA/n-3 LC-PUFA and insulin secretion and sensitivity B Ahrén et al that treatment did not affect b-cell function or insulin sensitivity (Figure 1 ).
Effects of CLA/n-3 LC-PUFA or control oil in older subjects Similarly, after treatment in the older lean subjects, the glucose, insulin and C-peptide concentration curves after meal ingestion were almost superimposable. No effect of CLA/n-3 LC-PUFA was observed on b-cell function or insulin sensitivity (Table 4) . However, in contrast to the young subjects, estimated insulin sensitivity (oral glucose insulin sensitivity) was reduced in the older obese subjects (P ¼ 0.024). This reduction was associated with a trend toward increased basal concentrations of glucose, insulin and C-peptide, although these changes were not significantly different from those in the control oil group (Figure 2) .
Discussion
This study investigated whether a combination of CLA and n-3 LC-PUFA had any effect on insulin secretion and sensitivity in young and older, lean and obese men. The design allows a solid conclusion in humans as to whether this combination could fulfill potential expectations from rodent studies of beneficial effects of CLA or n-3 LC-PUFAs Abbreviations: CLA, conjugated linoleic acid; ISR, insulin secretory rate; LC-PUFA, long-chain polyunsaturated fatty acids. Values are changes from baseline. Data were not significantly different between CLA/n-3 LC-PUFA vs control oil (P40.05), except when marked with asterisk (*P ¼ 0.024).
Values are means ± s.e.m. ISR at ref ¼ insulin secretory rate at the reference glucose level of 5.0 mmol/l; glucose sensitivity ¼ mean slope of the dose-response relationship between glucose concentration and insulin secretory rate.
CLA/n-3 LC-PUFA and insulin secretion and sensitivity B Ahrén et al (Ikemoto et al., 1996; Park et al., 1997; Houseknecht et al., 1998; West et al., 1998; Hamura et al., 2001; Ryder et al., 2001; Roche et al., 2002; Ruxton, 2004; Poirier et al., 2005) . The dose of CLA (2.28 g/d) was chosen to represent both the dose available in commercially available CLA supplements (for example, there is 2 g of CLA in two capsules of 'Tonalin') and the dosage used in previous supplementation trials in which insulin sensitivity was compromised (Risérus et al., 2002; Moloney et al., 2004) . The dose of n-3 LC-PUFAs (1.53 g eicosapentanoic acid and docosahexaenoic acid) was selected as beneficial effects of n-3 fish oils on insulin sensitivity have previously been reported using similar doses (1.8 g eicosapentanoic acid and docosahexaenoic acid; Delarue et al., 2006) . This study shows that fasting and postprandial glucose and insulin levels did not change significantly after CLA/n-3 LC-PUFA compared with control oil in any of the study groups. CLA/n-3 LC-PUFA did not change the insulin or C-peptide levels during meal ingestion or the model-derived parameters of b-cell function. In contrast, a reduction in the estimated insulin sensitivity after CLA/n-3 LC-PUFA was seen in the older obese subjects. These results suggest that the combination of CLA and n-3 LC-PUFA does not alter insulin secretion or action in young obese or in young or older lean men, whereas CLA/n-3 LCPUFA reduces insulin sensitivity in older obese subjects. This is similar to the insulin insensitivity induced by CLA observed in middle-aged subjects (Risérus et al., 2002) . It is unlikely that a longer treatment would result in a different outcome as the previous study reported a significant impairment of insulin sensitivity after 12 weeks of treatment. There was a trend for control oil supplementation to have an age-dependent effect on the estimated insulin sensitivity in the two obese groups, that is, it was reduced in the younger but increased in the older Young -Overweight Figure 1 Plasma levels of glucose, insulin and C-peptide (mean±s.e.m.) after ingestion of a standard meal after 12-week supplementation with CLA and n-3 LC-PUFA or control oil in young lean or obese men.
CLA/n-3 LC-PUFA and insulin secretion and sensitivity B Ahrén et al obese subjects. However, these changes were not significant and the only consistent change was a reduction in estimated insulin sensitivity after CLA/n-3 LC-PUFA in the older obese subjects.
The mechanisms underlying the effects of n-3 LC-PUFA and CLA on insulin sensitivity are complex. n-3 LC-PUFAs have been shown to influence gene expression in both liver and white adipose tissue to improve metabolic health (Al-Hasani and Joost, 2005) as well as acting as antiinflammatory agents and increasing adiponectin levels, which in turn improve insulin sensitivity (Todoric et al., 2006) . CLAs have been reported to influence gene expression in white adipose tissue and to increase and decrease insulin sensitivity and to be both pro-and anti-inflammatory depending on the animal model tested and the isomer used (Chung et al., 2005 , Wargent et al., 2005 Poirier et al., 2006; Moloney et al., 2007; Zhou et al., 2008) . Although the design of this study and the relatively small sample size meant that comparisons within the same volunteer, that is the effect of CLA/n-3 PUFA vs control oil supplementation, had greater statistical power than comparisons between volunteers, that is age vs adiposity, the results indicate that both adiposity and age are also factors that may modulate the effects of these dietary fatty acids in humans.
The effects of the CLA and n-3 LC-PUFA combination on parameters of body composition demonstrated that there were no significant changes in body composition or fat distribution when comparing the combination with control oil treatment in any group except in the young obese subjects who showed a small increase in fat-free mass together with a decrease in abdominal fat mass (Sneddon et al., 2008) . Therefore, a CLA plus n-3 LC-PUFA Older -Overweight Figure 2 Plasma levels of glucose, insulin and C-peptide (mean ± s.e.m.) after ingestion of a standard meal after 12-week supplementation with CLA and n-3 LC-PUFA or control oil in older lean or obese men.
CLA/n-3 LC-PUFA and insulin secretion and sensitivity B Ahrén et al combination-induced change in body adiposity was unlikely to account for the reduced insulin sensitivity observed in the older obese group. In mice fed a normal chow diet, 12 weeks supplementation with CLA and n-3 LC-PUFA induced insulin insensitivity associated with reduced adiponectin levels and augmented insulin secretion. However, the increase in insulin secretion was insufficient to counteract the insulin insensitivity, resulting in glucose intolerance (Sörhede Winzell et al., 2006) . However, no effect was evident in high-fat-fed mice, suggesting that high-fat diet prevented the effects of the CLA and n-3 LC-PUFA combination. In this study, we demonstrate a reduction in insulin sensitivity after treatment with CLA/n-3 LCPUFA, exclusively in the older obese subjects. These results show that mice are more prone to the effects of this combined supplementation than humans. Nevertheless, these differences may be related to different doses of CLA and n-3 LC-PUFA. In the mice study, CLA and LC-PUFA comprised 2% of the dietary intake, which is equivalent to 28% of dietary fat intake in the normal chow diet-fed mice (Sörhede Winzell et al., 2006) and in this study, only approximately 4.2% of the daily fat intake was from these supplements. However, a previous study in mice showed that a combination of n-3 LC-PUFA and CLA reversed the effects induced by CLA alone, including hepatomegaly, liver fat, decreased fat mass and changes in leptin and adiponectin levels (Ide, 2005) .
It has been reported that CLA alone induces insulin insensitivity in humans (Risérus et al., 2002; Moloney et al., 2004; Riserus et al., 2004) . We did not observe this with the combination of CLA and n-3 LC-PUFA, except in the older obese subjects. This could suggest that n-3 LC-PUFA would reverse the effects of CLA, in agreement with the combined supplementation studies in mice (Ide, 2005) , providing a mechanistic basis for the findings of this study.
The baseline data in this study showed clear differences between obese and lean subjects. This is expected and in agreement with a number of other studies (Ferrannini et al., 2004; Despres and Lemieux, 2006; Kahn et al., 2006) . When comparing lean vs obese subjects, glucose tolerance, as judged from the 2-h glucose level after meal ingestion or the AUC glucose , was not different. Thus, the increase in insulin secretion in obese subjects was sufficient to match the reduced insulin sensitivity.
In summary, this study in healthy lean and obese young and older subjects indicates that the combination of CLA and n-3 LC-PUFA does not affect either glucose levels or insulin secretion from the b cells or insulin sensitivity in young or older lean subjects, whereas a reduction of insulin sensitivity by CLA/n-3 LC-PUFA occurred in older subjects with obesity. The results support the contention that n-3 LC-PUFA can, in most cases, decrease the effects of CLA in decreasing insulin sensitivity. However, the overall effect of the combination does not improve insulin secretion or sensitivity in humans except in the older obese where it actually decreases insulin sensitivity.
